Transcutaneous electrical nerve stimulation (TENS) is a therapy that has been around for decades. It is used to treat pain and a few other conditions, but over those decades it has gotten a bit stale. New companies, though, are taking TENS therapy to a new level and NeuroMetrix is one of the leaders in this field.

The company was showing off for the first time its Quell 2.0 TENS device at CES 2019. It is smaller than the company’s original product, but sports a larger battery that can provide more juice and more therapy sessions per charge. It is actually more powerful than any other TENS device on the market and is about ten times more powerful than your typical over-the-counter TENS unit.

The new Quell 2.0 also comes with new capabilities through the companion app that provides coaching and helps to optimize therapy. There’s also an “Intensive Therapy” option that apparently users machine learning to best match therapy to the individual patient’s needs.

We got a chance to speak to Dr. Shai Gozani, CEO of NeuroMetrix, to find out more about the new product and other developments in the company:

Flashbacks: Neurostimulation Enhanced by Digital Health: Interview with CEO of NeuroMetrix…NeuroMetrix Quell Neurostimulator for Day and Night Use Now Cleared in Europe…NeuroMetrix Sensus Diabetic Pain Management System…Quell, A Non-Medication Solution for Chronic Pain: Interview with CEO Shai Gozani…NeuroMetrix Pain Management Technology Cleared for OTC Use by FDA…More About Quell, NeuroMetrix’s Smartphone-Connected Neurostimulator…

Link: NeuroMetrix homepage…

Source link